Clinuvel Pharmaceuticals (UR9) Price & Analysis

0 Followers

UR9 Stock Chart & Stats

CHF5.74

CHF0.00(0.00%)

At close: Jul 24 4:00 PM EDT

CHF5.74

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF3.94 - CHF6.26

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

CHF213.72M

Enterprise ValueCHF272.15M

Total Cash (Recent Filing)CHF252.06M

Total Debt (Recent Filing)CHF1.94M

Price to Earnings (P/E)10.6

Beta1.24

Next Earnings

Feb 23, 2027

EPS Estimate

0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.68

Shares Outstanding50,487,125

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-2.72

Price to Book (P/B)1.88

Price to Sales (P/S)5.45

P/FCF Ratio14.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF9.55

Price Target Upside66.36% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)0.39

Revenue Forecast (FY)CHF54.08M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetNear-zero leverage materially reduces financial risk and interest burden, preserving flexibility to fund research, commercialization, or other priorities internally. The steady increase in equity also provides a durable capital base, helping the company withstand weaker operating periods without relying heavily on debt.

Strong Cash ConversionOperating cash flow exceeding net income indicates that reported earnings are converting into cash effectively, supporting business self-funding and financial resilience. Consistently positive free cash flow gives Clinuvel capacity to sustain operations and invest in development while limiting dependence on external capital.

Established ProfitabilitySustained high gross and net margins demonstrate that the commercial business has historically generated meaningful profit from its revenue base. This profitability can support continued commercialization and research investment, while providing a stronger foundation than an early-stage company dependent on future funding.

Bears Say

Revenue Contraction And Margin ResetThe return to negative revenue growth interrupts the prior expansion trend and raises concern about the durability of commercial momentum. A sharp gross-margin reduction may also weaken operating leverage, making future earnings more sensitive to product mix, pricing, or cost changes even though net margin remains healthy.

Slowing Free Cash Flow GrowthPositive free cash flow remains a strength, but its 2026 contraction signals that cash-generation momentum has weakened alongside the softer operating trajectory. If sustained, slower cash growth could reduce the pace at which Clinuvel funds research, commercialization, or shareholder returns from internal resources.

Declining Return On EquityFalling return on equity indicates that the company is generating less profit relative to its accumulated equity base than it did previously. This may reflect moderating profitability or a faster-growing capital base, and it reduces the efficiency of shareholder capital deployment even with minimal balance-sheet leverage.

Clinuvel Pharmaceuticals News

Clinuvel Moves to Enter US$1.3bn ACTH Market with EU Filing for NEURACTHEL

The latest announcement is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals, a specialist in melanocortin-based therapies...

1d ago

Clinuvel Pharmaceuticals Reports Cessation of Securities in October 6-K Filing

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an announcement. On October 15, 2026, Clinuvel Pharmaceuticals filed a Form...

16d ago

Clinuvel Pharmaceuticals Updates U.S. Investors on New and Ceased Securities via Form 6-K

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an update. On October 5, 2026, Clinuvel Pharmaceuticals filed several regulatory...

24d ago

Clinuvel Pharmaceuticals Reports Expiry of 61,272 Performance Rights

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an update. Clinuvel Pharmaceuticals has reported the cessation of 61,272 performance...

25d ago

Clinuvel Seeks ASX Quotation for Additional Ordinary Shares

The latest announcement is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals has applied for quotation of...

25d ago

Clinuvel urges stability ahead of AGM as board warns against potential spill

An update from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. Clinuvel Pharmaceuticals has called its 2026 Annual...

29d ago

Clinuvel Shows Sustained Vitiligo Repigmentation with SCENESSE Combo Therapy

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an announcement. Clinuvel Pharmaceuticals reported new clinical cases from its CUV105...

30d ago

Clinuvel Unveils ZEROKIN Single-Use Device for Controlled-Release Drug Delivery

Clinuvel Pharmaceuticals ( ($AU:CUV) ) has shared an announcement. On 8 September 2026, Clinuvel Pharmaceuticals announced it had...

2M ago

Clinuvel Unveils ZEROKIN Device to Target Growing Self-Injection Market

The latest announcement is out from Clinuvel Pharmaceuticals ( ($AU:CUV) ). Clinuvel Pharmaceuticals has completed development of ZEROKIN,...

2M ago

Vanguard Drops Below Substantial Holder Threshold in Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. Vanguard Group, including its controlled entities such as Vanguard...

2M ago

UR9 FAQ

What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?

Clinuvel Pharmaceuticals Limited lowest stock price was CHF3.94 and its highest was CHF6.26 in the past 12 months.

What is Clinuvel Pharmaceuticals Limited’s market cap?

Clinuvel Pharmaceuticals Limited’s market cap is CHF213.72M.

When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?

Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Feb 23, 2027 which is in 115 days.

How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?

Clinuvel Pharmaceuticals Limited released its earnings results on Aug 27, 2026. The company reported CHF0.271 earnings per share for the quarter, missing the consensus estimate of CHF0.289 by -CHF0.018.

Is Clinuvel Pharmaceuticals Limited overvalued?

According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clinuvel Pharmaceuticals Limited pay dividends?

Clinuvel Pharmaceuticals Limited does not currently pay dividends.

What is Clinuvel Pharmaceuticals Limited’s EPS estimate?

Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.14.

How many shares outstanding does Clinuvel Pharmaceuticals Limited have?

Clinuvel Pharmaceuticals Limited has 50,487,125 shares outstanding.

What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?

Clinuvel Pharmaceuticals Limited reported an EPS of CHF0.271 in its last earnings report, missing expectations of CHF0.289. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in CH:UR9

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clinuvel Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

13.00%

Trailing 12-Months

Asset Growth

14.85%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

Clinuvel Pharmaceuticals (UR9) Earnings & Revenues

Historic Earnings Reports

UR9 Company Deck

UR9 Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.View all CH:UR9 earnings summaries

UR9 Stock 12 Month Forecast

Average Price Target

CHF9.55

▲(66.36% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"CHF3","8":"CHF8","13":"CHF13","18":"CHF18","23":"CHF23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.953100155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF22.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.5491905225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF9.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.08833845,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF4.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,8,13,18,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.649,6.057007704230769,7.4650154084615385,8.873023112692309,10.281030816923078,11.689038521153847,13.097046225384616,14.505053929615386,15.913061633846155,17.321069338076924,18.729077042307694,20.137084746538463,21.545092450769232,{"y":22.953100155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.649,5.0259377325,5.402875465,5.7798131975,6.15675093,6.5336886625,6.9106263949999995,7.2875641275,7.66450186,8.0414395925,8.418377325,8.7953150575,9.17225279,{"y":9.5491905225,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.649,4.605872188461539,4.562744376923077,4.519616565384616,4.476488753846154,4.433360942307693,4.39023313076923,4.347105319230769,4.3039775076923075,4.260849696153846,4.2177218846153846,4.174594073076923,4.131466261538462,{"y":4.08833845,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.715,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.715,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.649,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >